MHY446 induces apoptosis via reactive oxygen species-mediated endoplasmic reticulum stress in HCT116 human colorectal cancer cells.

IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES
Journal of Chemotherapy Pub Date : 2024-10-01 Epub Date: 2023-12-06 DOI:10.1080/1120009X.2023.2286757
Yu Ra Ahn, Jung Yoon Jang, Yong Jung Kang, Hye Jin Oh, Min Kyung Kang, Dahye Yoon, Hyung Sik Kim, Hyung Ryong Moon, Hae Young Chung, Nam Deuk Kim
{"title":"MHY446 induces apoptosis via reactive oxygen species-mediated endoplasmic reticulum stress in HCT116 human colorectal cancer cells.","authors":"Yu Ra Ahn, Jung Yoon Jang, Yong Jung Kang, Hye Jin Oh, Min Kyung Kang, Dahye Yoon, Hyung Sik Kim, Hyung Ryong Moon, Hae Young Chung, Nam Deuk Kim","doi":"10.1080/1120009X.2023.2286757","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigated the potential of a newly synthesized histone deacetylase (HDAC) inhibitor, MHY446, in inducing cell death in HCT116 colorectal cancer cells and compared its activity with that of suberoylanilide hydroxamic acid (SAHA), a well-known HDAC inhibitor. The results showed that MHY446 increased the acetylation of histones H3 and H4 and decreased the expression and activity of HDAC proteins in HCT116 cells. Additionally, MHY446 was confirmed to bind more strongly to HDAC1 than HDAC2 and inhibit its activity. <i>In vivo</i> experiments using nude mice revealed that MHY446 was as effective as SAHA in inhibiting HCT116 cell-grafted tumor growth. This study also evaluated the biological effects of MHY446 on cell survival and death pathways. The reactive oxygen species (ROS) scavenger <i>N</i>-acetyl-L-cysteine (NAC) confirmed that ROS play a role in MHY446-induced cell death by reducing poly(ADP-ribose) polymerase cleavage. MHY446 also induced cell death <i>via</i> endoplasmic reticulum (ER) stress by increasing the expression of ER stress-related proteins. NAC treatment decreased the expression of ER stress-related proteins, indicating that ROS mediate ER stress as an upstream signaling pathway and induce cell death. While MHY446 did not exhibit superior HDAC inhibition efficacy compared to SAHA, it is anticipated to provide innovative insights into the future development of therapeutic agents for human CRC by offering novel chemical structure-activity relationship-related information.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"483-500"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2023.2286757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

This study investigated the potential of a newly synthesized histone deacetylase (HDAC) inhibitor, MHY446, in inducing cell death in HCT116 colorectal cancer cells and compared its activity with that of suberoylanilide hydroxamic acid (SAHA), a well-known HDAC inhibitor. The results showed that MHY446 increased the acetylation of histones H3 and H4 and decreased the expression and activity of HDAC proteins in HCT116 cells. Additionally, MHY446 was confirmed to bind more strongly to HDAC1 than HDAC2 and inhibit its activity. In vivo experiments using nude mice revealed that MHY446 was as effective as SAHA in inhibiting HCT116 cell-grafted tumor growth. This study also evaluated the biological effects of MHY446 on cell survival and death pathways. The reactive oxygen species (ROS) scavenger N-acetyl-L-cysteine (NAC) confirmed that ROS play a role in MHY446-induced cell death by reducing poly(ADP-ribose) polymerase cleavage. MHY446 also induced cell death via endoplasmic reticulum (ER) stress by increasing the expression of ER stress-related proteins. NAC treatment decreased the expression of ER stress-related proteins, indicating that ROS mediate ER stress as an upstream signaling pathway and induce cell death. While MHY446 did not exhibit superior HDAC inhibition efficacy compared to SAHA, it is anticipated to provide innovative insights into the future development of therapeutic agents for human CRC by offering novel chemical structure-activity relationship-related information.

MHY446 通过活性氧介导的内质网应激诱导 HCT116 人结肠直肠癌细胞凋亡。
本研究探讨了一种新合成的组蛋白去乙酰化酶(HDAC)抑制剂MHY446诱导HCT116结直肠癌细胞死亡的潜力,并将其活性与一种著名的HDAC抑制剂--亚伯酰苯胺羟肟酸(SAHA)进行了比较。结果表明,MHY446 增加了组蛋白 H3 和 H4 的乙酰化,降低了 HDAC 蛋白在 HCT116 细胞中的表达和活性。此外,还证实 MHY446 与 HDAC1 的结合比与 HDAC2 的结合更强,并能抑制其活性。使用裸鼠进行的体内实验表明,MHY446 在抑制 HCT116 细胞移植的肿瘤生长方面与 SAHA 一样有效。本研究还评估了 MHY446 对细胞存活和死亡途径的生物效应。活性氧(ROS)清除剂 N-乙酰-L-半胱氨酸(NAC)证实,ROS 通过减少聚(ADP-核糖)聚合酶的裂解,在 MHY446 诱导的细胞死亡中发挥作用。MHY446 还通过增加内质网(ER)应激相关蛋白的表达诱导细胞死亡。NAC 处理降低了 ER 应激相关蛋白的表达,表明 ROS 作为上游信号通路介导 ER 应激并诱导细胞死亡。虽然与 SAHA 相比,MHY446 没有表现出更优越的 HDAC 抑制效果,但通过提供新的化学结构-活性关系相关信息,它有望为未来开发人类 CRC 治疗药物提供创新性见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Chemotherapy
Journal of Chemotherapy 医学-药学
CiteScore
3.70
自引率
0.00%
发文量
144
审稿时长
6-12 weeks
期刊介绍: The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信